** Shares of Lucid Diagnostics LUCD.O down 24.2% to $1.25 before the bell after overnight follow-on priced
** New York-based commercial-stage co late Weds sold 12.5 mln shares at $1.20 for $15 mln gross proceeds
** Offering priced at 27.3% discount to last sale
** The subsidiary of PAVmed Inc PAVM.O plans to use net proceeds for working capital, general purposes
** LUCD had ~90.75 mln shares outstanding as of Mar 20, per most recent 10-k filing, giving it $150 mln market cap
** Co's flagship product, the EsoGuard Esophageal DNA Test, is used to screen for esophageal precancer and cancer in at-risk gastroesophageal reflux disease (GERD) patients
** Stock ended 2024 at 82 cents
** Canaccord Genuity sole bookrunner for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。